Source-grounded facts extracted from BAXTER INTERNATIONAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BAXTER INTERNATIONAL INC shareholders approved Advisory vote on executive compensation at the 2023-05-02 meeting.
“By the following vote, stockholders approved, on an advisory basis, the 2022 compensation paid to the Company’s named executive officers: For Against Abstain Broker Non-Votes 308,247,917 88,194,108 1,067,883 45,684,471”
BAXTER INTERNATIONAL INC shareholders approved Election of ten nominees for director at the 2023-05-02 meeting.
“The ten nominees for director were elected as follows: Nominee For Against Abstain Broker Non-Votes José (Joe) E. Almeida 361,852,100 33,701,315 1,956,493 45,684,471 Michael F. Mahoney 383,057,652 13,911,184 541,072 45,684,471 Patricia B. Morrison 393,043,858 3,957,883 508,167 45,684,471 Stephen N. Oesterle 387,974,278 8,983,436 552,194 45,684,471 Nancy M. Schlichting 379,485,505 17,509,528 514,875 45,684,471 Brent Shafer 392,915,009 4,034,031 560,868 45,684,471 Cathy R. Smith 362,712,574 34,285,979 511,355 45,684,471 Amy A. Wendell 385,028,500 11,967,719 513,689 45,684,471 David S. Wilkes 393,039,608 3,926,902 543,398 45,684,471 Peter M. Wilver 381,620,681 15,310,118 579,109 45,684,471”
BAXTER INTERNATIONAL INC reported first quarter of 2023 results: revenue $3.65 billion, net income $44 million, EPS $0.09 per diluted share. Guidance initiated.
“First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis 1 • First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09; Adjusted EPS totaled $0.59”
BAXTER INTERNATIONAL INC amended Euro Amendment with J.P. Morgan SE valued at 200,000,000 (effective 2023-03-13).
“On March 13, 2023, Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers (the " Euro Borrowers "), their existing lender group, Baxter, as Guarantor, and J.P. Morgan SE, as Administrative Agent, entered into a second guaranty amendment (the " Euro Amendment ") to the existing amended and restated guaranty agreement, dated as of October 1, 2021, as amended by that certain Second Amendment, dated as of September 28, 2022, by Baxter in favor of J.P. Morgan SE in connection with the existing €200 million revolving credit facility, dated as of December 20, 2019, as amended by that certain First Amendment, dated as of October 1, 2021, and that certain Second Amendment, dated as of September 28, 2022, among the Euro Borrowers, as Borrowers, various lenders, and J.P. Morgan SE, as Administrative Agent.”
BAXTER INTERNATIONAL INC amended USD Revolving Third Amendment with JPMorgan Chase Bank, National Association valued at 2,500,000,000 (effective 2023-03-13).
“On March 13, 2023, Baxter entered into a third amendment (the " USD Revolving Third Amendment ") to the existing $2.5 billion, five-year revolving credit agreement, dated as of September 30, 2021, as amended by that certain First Amendment, dated as of September 28, 2022, and that certain Second Amendment, dated as of September 28, 2022, among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent.”
BAXTER INTERNATIONAL INC amended Term Loan Third Amendment with JPMorgan Chase Bank, National Association valued at 4,000,000,000 (effective 2023-03-13).
“On March 13, 2023, Baxter International Inc. (" Baxter ") entered into a third amendment (the " Term Loan Third Amendment ") to the existing $4.0 billion term loan credit facility, dated as of September 30, 2021, as amended by that certain First Amendment, dated as of September 28, 2022, and that certain Second Amendment, dated as of September 28, 2022, among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent.”
Alok Sonig was appointed as Executive Vice President and Group President, Pharmaceuticals at BAXTER INTERNATIONAL INC.
“Mr. Alok Sonig was appointed as the Company’s Executive Vice President and Group President, Pharmaceuticals.”
Reaz Rasul was appointed as Executive Vice President and Group President, Healthcare Systems and Technologies at BAXTER INTERNATIONAL INC.
“Mr. Reaz Rasul was appointed as the Company’s Executive Vice President and Group President, Healthcare Systems and Technologies.”
Heather Knight was appointed as Executive Vice President and Group President, Medical Products and Therapies at BAXTER INTERNATIONAL INC.
“Ms. Heather Knight was appointed as the Company’s Executive Vice President and Group President, Medical Products and Therapies.”
D. Brent Shafer was appointed as Lead Independent Director at BAXTER INTERNATIONAL INC.
“the Board also appointed Mr. D. Brent Shafer as the Board’s Lead Independent Director, effective April 28, 2023.”
Albert P.L. Stroucken retired as Director at BAXTER INTERNATIONAL INC.
“Mr. Stroucken’s term will expire on April 28, 2023.”
Thomas F. Chen retired as Director at BAXTER INTERNATIONAL INC.
“On February 13, 2023, Mr. Thomas F. Chen notified Baxter International Inc. (the “Company” or “Baxter”) of his decision to retire from the Board of Directors of the Company (the “Board”), effective as of April 28, 2023.”
BAXTER INTERNATIONAL INC reported financial results for the fourth quarter and full year ended Dec. 31, 2022.
“On February 9, 2023 , Baxter International Inc. (the Company) issued an earnings press release for the period ended December 31, 2022.”
Giuseppe Accogli resigned as Executive Vice President and Chief Operating Officer at BAXTER INTERNATIONAL INC.
“On January 4, 2023, Giuseppe Accogli, the Executive Vice President and Chief Operating Officer of Baxter International Inc. (“Baxter” or the “Company”), resigned as Executive Vice President and Chief Operating Officer of the Company effective immediately and no longer serves as an executive officer of the Company.”
BAXTER INTERNATIONAL INC reported third quarter of 2022 results: revenue $3.8 billion, net income ($2.9 billion), EPS ($5.83).
“attachments, is furnished as Exhibit 99.1 to this report. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2022 RESULTS • Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis 1 • Third-quarter U.S. GAAP earnings (loss) per share (EPS) were”
Peter S. Hellman retired as Director at BAXTER INTERNATIONAL INC.
“On May 4, 2022, Peter S. Hellman notified the Company of his decision to retire from the Board, effective as of June 30, 2022.”
Peter M. Wilver was appointed as Director at BAXTER INTERNATIONAL INC.
“On May 3, 2022, Baxter International Inc. (the “Company”) appointed each of D. Brent Shafer and Peter M. Wilver to its Board of Directors (the “Board”), with such appointments to become effective on May 10, 2022.”
D. Brent Shafer was appointed as Director at BAXTER INTERNATIONAL INC.
“On May 3, 2022, Baxter International Inc. (the “Company”) appointed each of D. Brent Shafer and Peter M. Wilver to its Board of Directors (the “Board”), with such appointments to become effective on May 10, 2022.”
John D. Forsyth retired as Director at BAXTER INTERNATIONAL INC.
“On December 9, 2021, Mr. John D. Forsyth notified the Company of his decision to retire from the Board, and the Board’s Nominating, Corporate Governance & Public Policy Committee and Compensation Committee, in each case effective as of May 1, 2022.”
Nancy M. Schlichting was appointed as Director at BAXTER INTERNATIONAL INC.
“On December 13, 2021, the Company appointed Ms. Nancy M. Schlichting to the Board of Directors of the Company”
Giuseppe Accogli was appointed as Executive Vice President and Chief Operating Officer at BAXTER INTERNATIONAL INC.
“On November 29, 2021, Baxter International Inc. (the “Company”) appointed Giuseppe Accogli, age 51, to serve as the Company’s Executive Vice President and Chief Operating Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.